MPCCC investigators succeed in latest VCA funding round

The latest Victorian Cancer Agency funding round has injected $12.2 million to support cancer research projects designed to fast-track research into clinical practice and develop new treatments that deliver better cancer care.

MPCCC would like to congratulate Dr Luc Furic from Monash University, who was awarded a VCA Mid-career Research Fellowship for his project “Targeting MYC driven prostate cancer by combining targeted radionuclide therapy with ribosome biogenesis inhibition as a new therapy in castration resistant”

Congratulations also go to the investigators from MPCCC’s health services who are to collaborate in the VCA’s latest Translational Research Project Grants, including:

A/Prof Jake Shortt, Monash Health; Project: Development of a novel combined radiotherapy / immunotherapy approach in patients with diffuse large B cell lymphoma

Dr Andrew Haydon The Alfred and Associate Professor Philip Parente, Eastern Health; Project: Novel approaches for overcoming resistance to therapies for advanced melanoma

Professor Ian Davis, Eastern Health Dr Luc Furic, Monash University and Dr David Pook Monash Health; Project: Combination of radionuclide 177Lu-PSMA therapy with pembrolizumab in patients with metastatic castration-resistant prostate cancer

and Associate Professor Andrew Wei, Monash University, Lead Applicant; Project: The International Acute Myeloid Leukaemia Platform Consortium

The VCA grants were announced on 17 February alongside a $20 million investment over four years for the Victorian Comprehensive Cancer Centre (VCCC) alliance to deliver new clinical trials for cancer patients.

“We’re putting cancer patients first and investing in world leading cancer research and clinical trials that have the power to save lives and one day find a cure” said Victorian Minister for Health, Jill Hennessy.

Further information about each of the VCA funded projects can be found at the Victorian Cancer Agency website.